Annonaceous acetogenins (ACGs) nanosuspensions based on a self-assembly stabilizer and the significantly improved anti-tumor efficacy

• Published in: Colloids and surfaces, B, Biointerfaces B, Biointerfaces, 2016-09, Vol.145, p.319-327
• Main Authors: Hong, Jingyi, Li, Yanhong, Xiao, Yao, Li, Yijing, Guo, Yifei, Kuang, Haixue, Wang, Xiangtao
• Format: Article
• Language: English
• Subjects: Acetogenins - pharmacology; Animals; Annonaceous acetogenins; Anti-tumor activity; Anticancer properties; Antineoplastic Agents - pharmacology; Cancer; Cyclodextrin; Drug Liberation; Drugs; Effectiveness; HeLa Cells; Hemolysis - drug effects; Hep G2 Cells; Humans; In vitro testing; Inhibitory Concentration 50; Male; Mice; Mice, Inbred ICR; Nanoparticles - chemistry; Nanostructure; Nanosuspensions; Particle Size; Rats; Self assembly; Self-assembly stabilizer; Suspensions - chemistry
• ISSN: 0927-7765; 1873-4367
• DOI: 10.1016/j.colsurfb.2016.05.012

[Display omitted] •HP-β-CD and soybean lecithin were self-assembled into a novel stabilizer.•ACGs were made into nanosuspensions for the first time with a high drug payload.•ACGs-NSps had significantly enhanced cytotoxicity compared with ACGs solution.•ACGs-NSps significantly improved ACGs’ antitumor efficacy in vivo. Annonaceous acetogenins (ACGs) have exhibited antitumor activity against various cancers. However, these substances’ poor solubility has limited clinical applications. In this study, hydroxypropyl-beta-cyclodextrin (HP-β-CD) and soybean lecithin (SPC) were self-assembled into an amphiphilic complex. ACGs nanosuspensions (ACGs-NSps) were prepared with a mean particle size of 144.4nm, a zeta potential of −22.9mV and a high drug payload of 46.17% using this complex as stabilizer. The ACGs-NSps demonstrated sustained release in vitro and good stability in plasma as well as simulated gastrointestinal fluid, and met the demand of both intravenous injection and oral administration. The ACGs-NSps demonstrated significantly increased cytotoxicity against Hela and HepG2 cancer cell lines compared to ACGs in solution (in vitro cytotoxicity assay). An in vivo study with H22-tumor bearing mice demonstrated that nanosuspensions significantly improved ACGs’ antitumor activity. When orally administered, ACGs-NSps achieved a similar tumor inhibition rate at 1/10th the dose of ACGs in an oil solution (47.94% vs. 49.74%, p>0.05). Improved therapeutic efficacy was further achieved when the ACGs-NSps were intravenously injected into mice (70.31%). With the help of nanosuspension technology, ACGs may be an effective antitumor drug for clinic use.